Limula secures USD 6.8 million to revolutionize Cell and Gene Therapy manufacturing
21.05.2024
The company's innovative technology integrates a bioreactor and centrifuge into a single vessel, promising significant advancements in process automation and efficiency. The new funds will accelerate the development of Limula's proprietary platform, potentially transforming the landscape of therapeutic manufacturing.
 Limula Co-Founders: Luc Henry (CEO), Yann Pierson (CTO), and Tom Eaton (COO)
|
 |
“When you’re in the early stages of a gold rush, it makes sense to be the one providing the tools,” says Luc Henry, Co-Founder and CEO of Limula. The Biotech startup, which is today announcing a USD 6.8 million funding round, wants to play that role as an investment in Cell and Gene Therapy, a hugely exciting new area of medicine, continues to accelerate.
Over the last decade, several Cell and Gene Therapy products have been approved in the USA and Europe, offering hope to millions with life-threatening conditions. However, 98% of patients can't access these treatments due to complex and costly manufacturing processes.
Limula has raised USD 6.8 million to advance its automated cell therapy manufacturing solution. The seed round was led by LifeX Ventures, Verve Ventures, Zühlke Ventures, Oxford Seed Fund, Lichtsteiner Foundation, W.A. de Vigier Foundation, and a line-up of private investors who have been supporting Limula’s vision from its inception.
Founded in 2020 by Dr. Yann Pierson, Dr. Luc Henry, and Dr. Thomas Eaton, Limula aims to simplify cell therapy production with novel technology. Current methods are labor-intensive and expensive, making treatments inaccessible to many patients. Limula's solution combines a bioreactor and centrifuge in a single device, streamlining production and reducing costs. This scalable technology supports cell therapy providers from pre-clinical trials to commercial manufacturing.
Limula Co-Founders: Luc Henry (CEO), Yann Pierson (CTO), and Tom Eaton (COO)
After proving the concept, Limula partnered with industry and academic groups, including the San Raffaele Telethon Institute for Gene Therapy in Italy, to refine its platform.
With the new funding, Limula will further develop its device to meet GMP (Good manufacturing practice) standards. Its technology promises to enhance the reach and accessibility of Cell and Gene Therapies, which have the potential to save millions of lives worldwide.
Limula participated in Venture Leaders Biotech in 2023, was ranked among the TOP 100 Swiss Startups in 2021 and 2023, and won the first stage of Venture Kick in 2018.
"ABC, the famous mantra of 'Always Be Closing,' transitioned into an 'Always Be Pitching' approach. In numerous networking events, you often have only the duration of an elevator ride to capture someone's interest. The journey served as excellent training for this skill, providing real-time feedback that was not only more candid but also more actionable compared to what we typically encounter in a Swiss context," highlighted Thomas Eaton, Co-Founder and CEO of Limula.
Over the last decade, several Cell and Gene Therapy products have been approved in the USA and Europe, offering hope to millions with life-threatening conditions. However, 98% of patients can't access these treatments due to complex and costly manufacturing processes.
Limula has raised USD 6.8 million to advance its automated cell therapy manufacturing solution. The seed round was led by LifeX Ventures, Verve Ventures, Zühlke Ventures, Oxford Seed Fund, Lichtsteiner Foundation, W.A. de Vigier Foundation, and a line-up of private investors who have been supporting Limula’s vision from its inception.
Founded in 2020 by Dr. Yann Pierson, Dr. Luc Henry, and Dr. Thomas Eaton, Limula aims to simplify cell therapy production with novel technology. Current methods are labor-intensive and expensive, making treatments inaccessible to many patients. Limula's solution combines a bioreactor and centrifuge in a single device, streamlining production and reducing costs. This scalable technology supports cell therapy providers from pre-clinical trials to commercial manufacturing.
Limula Co-Founders: Luc Henry (CEO), Yann Pierson (CTO), and Tom Eaton (COO)
After proving the concept, Limula partnered with industry and academic groups, including the San Raffaele Telethon Institute for Gene Therapy in Italy, to refine its platform.
With the new funding, Limula will further develop its device to meet GMP (Good manufacturing practice) standards. Its technology promises to enhance the reach and accessibility of Cell and Gene Therapies, which have the potential to save millions of lives worldwide.
Limula participated in Venture Leaders Biotech in 2023, was ranked among the TOP 100 Swiss Startups in 2021 and 2023, and won the first stage of Venture Kick in 2018.
"ABC, the famous mantra of 'Always Be Closing,' transitioned into an 'Always Be Pitching' approach. In numerous networking events, you often have only the duration of an elevator ride to capture someone's interest. The journey served as excellent training for this skill, providing real-time feedback that was not only more candid but also more actionable compared to what we typically encounter in a Swiss context," highlighted Thomas Eaton, Co-Founder and CEO of Limula.